Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
acebrophylline + desloratadine + montelukast sodium is a fixed-dose combination medication primarily used in the management of respiratory disorders such as asthma and chronic obstructive pulmonary disease (COPD), particularly when complicated by allergic rhinitis. The combination consists of three active ingredients with complementary mechanisms. Acebrophylline acts as both a bronchodilator and a mucolytic agent; it inhibits phosphodiesterase to increase cAMP levels and stimulates surfactant production to reduce mucus viscosity. Desloratadine is a non-sedating, long-acting H1-antihistamine that provides relief from allergic symptoms by selectively blocking peripheral histamine receptors. Montelukast sodium is a leukotriene receptor antagonist that targets the CysLT1 receptor to prevent airway edema, smooth muscle contraction, and inflammatory activity associated with cysteinyl leukotrienes. This triple combination is marketed by companies such as Neuracle Lifesciences in the Indian pharmaceutical market as a generic formulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on acebrophylline + desloratadine + montelukast sodium.